NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Tabletop particle accelerator could transform medicine and materials science 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Cancer is one of the leading causes of death in terms of medical issues in the world, affecting over 14 million patients on earth. The number of cancer patients is expected to grow by 2030, reaching over 21.7 million in the process. During that time, an estimated 13 million will have died due to their sickness or complications related to them. In response to the growing medical threat, an alliance comprised of major cancer organizations was formed to essentially create a cancer vaccine.
A significant number of cancer types are treatable, but due to lifestyle choices, work, stress factors, and even environmental influences, the health issue can still persist. In order to find a better way of addressing cancer, the Parker Institute for Cancer Immunotherapy partnered with the Cancer Research Institute and other organizations, Futurism reports.
The Parker Institute for Cancer Immunotherapy is the project of Sean Parker, the tech billionaire. Right now, the alliance counts 30 major organizations as members, including known universities and non-profit groups.
The focus of the alliance’s efforts will be research into neoantigens, which are considered genetic markers for specific cancer tumors. This makes them perfect for quickly detecting cancer within specific individuals, thus making early diagnosis much easier.
More than that, by crunching numbers via algorithms that analyze both DNA and RNA sequences, the presence of neoantigens is easier to detect. Once that happens, it would then be simpler for scientists to come up with a way to make it more visible to the immune system, thus destroying it before tumors appear.
Parker is particularly committed to ensuring that the alliance and its efforts bear fruit at some point, already having donated over $250 million to cancer research, TechCrunch reports. According to him, creating the alliance and directing their efforts to detect tumor markers is exactly what he wanted to achieve when he started his institute.
